Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01533155 · ClinicalTrials.gov registry record · Phase 1
Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 214
- Enrollment target
NCT01533155 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 214 participants.
The verdict
NCT01533155, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 214 participants
- Enrollment target
Study Summary
Study in healthy volunteers to investigate the effects of Quinidine on the Pharmacokinetics of NKTR-118
Interventions
- DRUG Morphine
- DRUG Quinidine
- DRUG Nektar 118
- DRUG Quinidine placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01533155
The ClinicalTrials.gov registry entry for NCT01533155 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Morphine is the first listed.
NCT01533155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01533155 about?
NCT01533155 is a clinical study titled "Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118". Study in healthy volunteers to investigate the effects of Quinidine on the Pharmacokinetics of NKTR-118
What is the current status of trial NCT01533155?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 214 participants. The study started on 2012-03. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01533155?
The interventions under investigation include: Morphine (DRUG), Quinidine (DRUG), Nektar 118 (DRUG), Quinidine placebo (DRUG).
Who is sponsoring clinical trial NCT01533155?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.